The Experts below are selected from a list of 273 Experts worldwide ranked by ideXlab platform

J G Pigman - One of the best experts on this subject based on the ideXlab platform.

  • PERFORMANCE OF A MODIFIED TURNED-DOWN GUARDRAIL End Treatment IN TRAFFIC ACCIDENTS. INTERIM REPORT
    1992
    Co-Authors: K R Agent, J G Pigman
    Abstract:

    The objective of this study was to report the results of the continued monitoring of the performance of the modified turned-down guardrail End Treatment (Type 7) in traffic accidents. Data for a total of 67 accidents involving the modified turned-down guardrail End Treatment were identified. Performance was classified as proper in 51 of the 61 accidents (84%) in which it was determined. In the majority of the accidents in which proper performance occurred, the vehicle either traveled onto the top of the guardrail beyond the breakaway section or broke through the breakaway posts and proceeded behind the guardrail. The performance of this "weakened turned-down" End Treatment has shown that continued use is warranted. Although full scale crash tests have not been conducted for this End Treatment, its performance in the field in actual accidents warrants further use. The rollover problem experienced with the original "stiff" turned-down design has been substantially reduced. The remaining question concerning the rollover problem relates to the small car. When roadway geometrics do not permit the guardrail End to be properly buried in a cut slope and conditions for the use of the BCT cannot be met, the Type 7 End Treatment provides a practical alternative.

  • PERFORMANCE OF GUARDRAIL End TreatmentS IN TRAFFIC ACCIDENTS. INTERIM REPORT
    1991
    Co-Authors: K R Agent, J G Pigman
    Abstract:

    The objective of this study was to report the results of the continued monitoring of the performance of guardrail End Treatments in traffic accidents. This report includes an analysis of accidents involving the breakaway-cable-terminal (BCT), Kentucky's version of the median BCT (MBCT), Kentucky's weakened turned down (Type 7), the Crash Cushion Attenuating Terminal (CAT), and the Breakmaster System. The report includes data for 349 accidents. This includes 232 accidents involving a BCT, 66 accidents involving a MBCT, 37 accidents involving the Type 7 turned-down End Treatment, 12 accidents involving the CAT, and 2 accidents involving the Breakmaster. Considering all accidents, the BCT performed properly in 76% of the accidents. A more detailed analysis showed the importance of installing the BCT using the parabolic flare. Use of the BCT End Treatment should be continued where geometrics permit. While the MBCT performed properly in 64% of all accidents, proper performance was 39% when only severe impacts were considered. Use of the MBCT should be eliminated or the MBCT modified due to the problems associated with impacts at shallow angles. Performance of the Type 7 weakened turned-down End Treatment was judged to be proper in 84% of the accidents involving this type. Performance appears to justify expanded use. The rollover problem experienced with the original "stiff" turned-down design has been significantly reduced. Performence was judged to be proper in 9 of the 12 accidents involving the CAT. Considering the results of CAT impacts in Kentucky, along with those in other states, permits the conclusion to be drawn that the CAT could be classified as operational. The Breakmaster system may provide an alternative to the CAT; however, additional accident data are needed to evaluate the performance of this system.

M Berry - One of the best experts on this subject based on the ideXlab platform.

  • Inhibition of glial scarring in the injured rat brain by a recombinant human monoclonal antibody to transforming growth factor-beta2.
    European Journal of Neuroscience, 1999
    Co-Authors: Ann Logan, Jonathan Alexander Green, A Hunter, Ronald Henry Jackson, M Berry
    Abstract:

    The transforming growth factor-betas (TGF-betas) are potent fibrogenic factors implicated in numerous central nervous system (CNS) pathologies in which fibrosis and neural dysfunction are causally associated. In this study, we aim to limit the fibrogenic process in a model of CNS scarring using a recombinant human monoclonal antibody, derived from phage display libraries and specific to the active form of the TGF-beta2 isoform. The implicit inference of the work was that, as such antibodies are potential pharmacological agents for the Treatment of human CNS fibrotic diseases, validation of efficacy in a mammalian animal model is a first step towards this End. Treatment of cerebral wounds with the anti-TGF-beta2 antibody led to a marked attenuation of all aspects of CNS scarring, including matrix deposition, formation of an accessory glial-limiting membrane, inflammation and angiogenesis. For example, in the wound, levels of: (i) the connective tissue components fibronectin, laminin and chondroitin sulphate proteoglycan; and (ii) wound-responsive cells including astrocytes and macrophages/microglia, were markedly reduced. Our findings suggest that such synthetic anti-fibrotic TGF-beta antibodies are potentially applicable to a number of human CNS fibrotic diseases to arrest the deposition of excessive extracellular matrix components, and maintain and/or restore functional integrity.

  • Inhibition of glial scarring in the injured rat brain by a recombinant human monoclonal antibody to transforming growth factor-??2
    European Journal of Neuroscience, 1999
    Co-Authors: Ann Logan, A Hunter, J. Green, R Jackson, M Berry
    Abstract:

    The transforming growth factor-betas (TGF-betas) are potent fibrogenic factors implicated in numerous central nervous system (CNS) pathologies in which fibrosis and neural dysfunction are causally associated. In this study, we aim to limit the fibrogenic process in a model of CNS scarring using a recombinant human monoclonal antibody, derived from phage display libraries and specific to the active form of the TGF-beta2 isoform. The implicit inference of the work was that, as such antibodies are potential pharmacological agents for the Treatment of human CNS fibrotic diseases, validation of efficacy in a mammalian animal model is a first step towards this End. Treatment of cerebral wounds with the anti-TGF-beta2 antibody led to a marked attenuation of all aspects of CNS scarring, including matrix deposition, formation of an accessory glial-limiting membrane, inflammation and angiogenesis. For example, in the wound, levels of: (i) the connective tissue components fibronectin, laminin and chondroitin sulphate proteoglycan; and (ii) wound-responsive cells including astrocytes and macrophages/microglia, were markedly reduced. Our findings suggest that such synthetic anti-fibrotic TGF-beta antibodies are potentially applicable to a number of human CNS fibrotic diseases to arrest the deposition of excessive extracellular matrix components, and maintain and/or restore functional integrity.

K R Agent - One of the best experts on this subject based on the ideXlab platform.

  • PERFORMANCE OF A MODIFIED TURNED-DOWN GUARDRAIL End Treatment IN TRAFFIC ACCIDENTS. INTERIM REPORT
    1992
    Co-Authors: K R Agent, J G Pigman
    Abstract:

    The objective of this study was to report the results of the continued monitoring of the performance of the modified turned-down guardrail End Treatment (Type 7) in traffic accidents. Data for a total of 67 accidents involving the modified turned-down guardrail End Treatment were identified. Performance was classified as proper in 51 of the 61 accidents (84%) in which it was determined. In the majority of the accidents in which proper performance occurred, the vehicle either traveled onto the top of the guardrail beyond the breakaway section or broke through the breakaway posts and proceeded behind the guardrail. The performance of this "weakened turned-down" End Treatment has shown that continued use is warranted. Although full scale crash tests have not been conducted for this End Treatment, its performance in the field in actual accidents warrants further use. The rollover problem experienced with the original "stiff" turned-down design has been substantially reduced. The remaining question concerning the rollover problem relates to the small car. When roadway geometrics do not permit the guardrail End to be properly buried in a cut slope and conditions for the use of the BCT cannot be met, the Type 7 End Treatment provides a practical alternative.

  • PERFORMANCE OF GUARDRAIL End TreatmentS IN TRAFFIC ACCIDENTS. INTERIM REPORT
    1991
    Co-Authors: K R Agent, J G Pigman
    Abstract:

    The objective of this study was to report the results of the continued monitoring of the performance of guardrail End Treatments in traffic accidents. This report includes an analysis of accidents involving the breakaway-cable-terminal (BCT), Kentucky's version of the median BCT (MBCT), Kentucky's weakened turned down (Type 7), the Crash Cushion Attenuating Terminal (CAT), and the Breakmaster System. The report includes data for 349 accidents. This includes 232 accidents involving a BCT, 66 accidents involving a MBCT, 37 accidents involving the Type 7 turned-down End Treatment, 12 accidents involving the CAT, and 2 accidents involving the Breakmaster. Considering all accidents, the BCT performed properly in 76% of the accidents. A more detailed analysis showed the importance of installing the BCT using the parabolic flare. Use of the BCT End Treatment should be continued where geometrics permit. While the MBCT performed properly in 64% of all accidents, proper performance was 39% when only severe impacts were considered. Use of the MBCT should be eliminated or the MBCT modified due to the problems associated with impacts at shallow angles. Performance of the Type 7 weakened turned-down End Treatment was judged to be proper in 84% of the accidents involving this type. Performance appears to justify expanded use. The rollover problem experienced with the original "stiff" turned-down design has been significantly reduced. Performence was judged to be proper in 9 of the 12 accidents involving the CAT. Considering the results of CAT impacts in Kentucky, along with those in other states, permits the conclusion to be drawn that the CAT could be classified as operational. The Breakmaster system may provide an alternative to the CAT; however, additional accident data are needed to evaluate the performance of this system.

Ann Logan - One of the best experts on this subject based on the ideXlab platform.

  • Inhibition of glial scarring in the injured rat brain by a recombinant human monoclonal antibody to transforming growth factor-beta2.
    European Journal of Neuroscience, 1999
    Co-Authors: Ann Logan, Jonathan Alexander Green, A Hunter, Ronald Henry Jackson, M Berry
    Abstract:

    The transforming growth factor-betas (TGF-betas) are potent fibrogenic factors implicated in numerous central nervous system (CNS) pathologies in which fibrosis and neural dysfunction are causally associated. In this study, we aim to limit the fibrogenic process in a model of CNS scarring using a recombinant human monoclonal antibody, derived from phage display libraries and specific to the active form of the TGF-beta2 isoform. The implicit inference of the work was that, as such antibodies are potential pharmacological agents for the Treatment of human CNS fibrotic diseases, validation of efficacy in a mammalian animal model is a first step towards this End. Treatment of cerebral wounds with the anti-TGF-beta2 antibody led to a marked attenuation of all aspects of CNS scarring, including matrix deposition, formation of an accessory glial-limiting membrane, inflammation and angiogenesis. For example, in the wound, levels of: (i) the connective tissue components fibronectin, laminin and chondroitin sulphate proteoglycan; and (ii) wound-responsive cells including astrocytes and macrophages/microglia, were markedly reduced. Our findings suggest that such synthetic anti-fibrotic TGF-beta antibodies are potentially applicable to a number of human CNS fibrotic diseases to arrest the deposition of excessive extracellular matrix components, and maintain and/or restore functional integrity.

  • Inhibition of glial scarring in the injured rat brain by a recombinant human monoclonal antibody to transforming growth factor-??2
    European Journal of Neuroscience, 1999
    Co-Authors: Ann Logan, A Hunter, J. Green, R Jackson, M Berry
    Abstract:

    The transforming growth factor-betas (TGF-betas) are potent fibrogenic factors implicated in numerous central nervous system (CNS) pathologies in which fibrosis and neural dysfunction are causally associated. In this study, we aim to limit the fibrogenic process in a model of CNS scarring using a recombinant human monoclonal antibody, derived from phage display libraries and specific to the active form of the TGF-beta2 isoform. The implicit inference of the work was that, as such antibodies are potential pharmacological agents for the Treatment of human CNS fibrotic diseases, validation of efficacy in a mammalian animal model is a first step towards this End. Treatment of cerebral wounds with the anti-TGF-beta2 antibody led to a marked attenuation of all aspects of CNS scarring, including matrix deposition, formation of an accessory glial-limiting membrane, inflammation and angiogenesis. For example, in the wound, levels of: (i) the connective tissue components fibronectin, laminin and chondroitin sulphate proteoglycan; and (ii) wound-responsive cells including astrocytes and macrophages/microglia, were markedly reduced. Our findings suggest that such synthetic anti-fibrotic TGF-beta antibodies are potentially applicable to a number of human CNS fibrotic diseases to arrest the deposition of excessive extracellular matrix components, and maintain and/or restore functional integrity.

Jerry G. Pigman - One of the best experts on this subject based on the ideXlab platform.

  • EVALUATION OF THE ET2000 GUARDRAIL End Treatment
    1997
    Co-Authors: Kenneth R. Agent, Jerry G. Pigman, Darrell Mcalister, Tim Gatewood
    Abstract:

    The objectives of this study were to monitor and report the performance of the ET2000 guardrail End Treatment design in traffic accidents. Data for a total of 34 collisions involving the ET2000 were identified. In most cases, an accident report was obtained and the damaged guardrail was inspected. The involved vehicle was inspected when available. Proper or improper performance of End Treatments in the collisions were judged based on whether it performed as designed. Field performance of the ET2000, as documented in traffic accidents, shows that, considering all the impacts, this End Treatment has performed properly. In several instances the End Treatment bent, rather than being pushed straight back, during the collision. This could typically be related to the angle at which impact occurred. Results warrant continued use of this End Treatment. However, its cost would not justify a widespread use on all types of highways.

  • Performance of a modified turned-down guardrail End Treatment in traffic accidents
    1992
    Co-Authors: Kenneth R. Agent, Jerry G. Pigman
    Abstract:

    The objective of this study was to report the results of the continued monitoring of the performance of the modified turned-down guardrail End Treatment (Type 7) in traffic accidents. Data for a total of 67 accidents involving the modified turned-down guardrail End Treatment were identified. Performance was classified as proper in 51 of the 61 accidents (84 percent) in which it was determined. In the majority of the accidents in which proper performance occurred, the vehicle either traveled onto the top of the guardrail beyond the breakaway section or broke through the breakaway posts and proceeded behind the guardrail. The performance of this 'weakened turned-down' End Treatment has shown that continued use is warranted. Although full scale crash tests have not been conducted for this End Treatment, its performance in the field in actual accidents warrants further use. The rollover problem experienced with the original 'stiff' turned-down design has been substantially reduced. The remaining question concerning the rollover problem relates to the small car. When roadway geometrics do not permit the guardrail End to be properly buried in a cut slope and conditions for the use of the BCT cannot be met, the Type 7 End Treatment provides a practical alternative.